

Key word index to Volume 3

- A549 cell line, 133
Aclarubicin, 233
ACR-CH, 233
Action spectrum, 139
Activated carbon, 233
Acute
 non-lymphoblastic leukemia, 475
 vision loss, 371
Additive (supra-, sub-) response, 577
Adriamycin, 133, 481, 615
Advanced breast cancer, 463
Aerobic glycolysis, 63
All-trans-retinoic acid, 541
Anaemia, 331
Analgesic activity, 91
Angiogenesis inhibitor, 293
Angiostatic antibiotic, 293
Anthracyclines, 175
Anti-
 cancer drugs, 109, 577
 emetics, 593
 estrogens, 147
 metastatic, 25
 neoplastic
 activity, 55, 493
 agents, 273
 proliferative
 activity, 513
 effects, 351, 525
 tumor, 25, 311
 activity, 95
 effects, 43
 response, 659
Antigen shedding, 659
Arylmethylaminopropanediol, 219
ATP level, 63
Autoantibodies, 541
5-Aza-2'-deoxycytidine, 281
Aza-alkyl-phospholipid, 599

Bacillus Calmette-Guérin, 39S*
Bladder cancer, 5S, 9S, 19S, 25S, 33S, 39S
 superficial, 25S, 29S
Basal cell carcinoma, 481
Benzohydroxamic acids, 273
1,3-Bis(2-chloroethyl)-1-nitrosourea, 267
Bleomycin, 659
Blood-brain barrier, 519
BM 41.400, 43

* S denotes page number in Supplement.
© 1992 Rapid Communications of Oxford Ltd
702 Anti-Cancer Drugs · Vol 3 · 1992
- BN 52205, 599
BN 52211, 599
Bone, 455
 marrow
 stromal cells, 647
 toxicity, 531
 metastases, 87
Brain tumor, 267
Breast
 cancer, 87, 147, 455, 471, 677
 advanced, 463
 neoplasm, 3
Bromocriptine, 555
Busulfan, 531

Camptothecins, 323
Cancer, 571
Carboplatin, 463, 665
Carcinoma *in situ*, 135
Cell
 cultures, 253
 cycle kinetics, 125
 electrophoresis, 427
 membranes, 443
 proliferation, 147, 245
Cellular growth inhibition, 629
Charcoal suspension, 261
Chemosensitivity, 687
Chemotherapeutic agents, 687
Chemotherapy, 79, 219, 323, 635
 local, 261
 locoregional, 17
 salvage, 471, 481
Chick embryo cells, 499
8-Chloro-adenosine, 485
8-Chloro-cAMP, 485
Chloroethylnitrosoureas, 401
Cis-dichlorodiammineplatinum(II) (cisplatin), 9
Cis-dimethylbis[sulfinylbis[methane]S]-platinum(II) (*cis*-dimethyl-platinum(II)), 9
Cisplatin, 155, 237, 375, 481, 665, 683
Cisplatinum, 513
Clavines, 609
Clinical trials, 571
Clodronate, 87
Clonogenic assay, 531
Coagulopathy, 211
Colon
 adenocarcinoma LS174T, 289
 tumor, 485
Colony formation, 121

Combination therapy, 195
Combined treatments, 407, 615
Congestive heart failure, 367
Controlled release, 175
Cortical blindness, 371
Corynebacterium parvum, 39
Cyclophosphamide, 427
Cycloplatin, 513
Cyclosporin A, 359
Cysteamine (2-chloroethyl)
 nitrosourea, 225
Cytochrome
 b₅, 623
 P450, 623
Cytosine-arabinoside, 475
Cytotoxic(s), 593
 compounds, 109
Cytotoxicity, 5S, 577

Dementia, 567
15-Deoxyspergualin, 293
2',2'-Difluorodeoxycytidine, 143
2,3-Dihydrophthalazine-1,4-dione, 55
5'-Deoxy-5-fluorouridine, 387
Deoxyribonucleotide pools, 379
Differentiation, 281
Dimethyl sulfoxide, 635
Disulfide, 651
DNA, 651
 adduct, 463
 binding, 687
 damage, 379
 directed enzymes, 499
 protein cycle, 379
 topoisomerases, 323
 synthesis, 499
 inhibitors, 273
Dobutamine, 367
Dopamine agonist, 555
Doxorubicin, 39S, 47, 101, 367, 443, 677
Drug
 combination, 513
 delivery system, 233, 261
 resistance, 39S, 641
 sensitivity assay, 641
 targeting, 175

Electrotherapy, 253
Elsamycin A, 677
Elymoclavine, 609
Emesis, 79
Entrapment, 95
Epididymis, 589

- Epipodophyllotoxins, 323
 Epirubicin, 19S, 25S, 593
 Ergolines, 609
 Ether
 lipids, 443
 phospholipids, 577
 Ethoglucid, 29S, 39S
 Etoposide, 24S, 359
 Experimental tumors, 253
- FdUMP derivative, 289
 Festuclavine, 609
 FK-565, 155
 Flavonoids, 525
 Flow cytometry, 419
 Fluorescence microscopy, 419
 5-Fluorouracil, 117, 261, 347, 413, 463
 Folinic acid, 347
 Fractionated X-irradiation, 395
- Galactose-6-mustard, 125
 Gastric
 adenocarcinoma, 331
 cancer, 211
 Gemcitabine, 143
 Glutathione, 623
 S-transferase, 623
 Granisetron, 79
 Growth modulation, 143
- Halocynthiaxanthin, 493
 Head and neck cancer, 347
 Heparin analog, 629
 Hepatic metastases, 101
 Hepatoma, 101
 Hepsulfam, 531
 1-Hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine, 43
 Hexamethylene bisacetamide, 163
 Histamine receptor, 427
 HIV-1, 163
 HL-60 leukemia cells, 647
 Hormonal carriers, 109
 5-HT₃, 79
 Human
 breast cancer, 677
 glioma cells, 407, 615
 malignant
 melanoma cells, 683
 mesothelioma, 687
 T lymphoma cells, 379
 tumor
 cells, 577
 cloning assay, 43
 xenograft, 387
 9-Hydroxybenfluron, 63
 Hydroxyurea, 347, 379
 Hyperthermia, 407
 Hypoxic tumor cell, 651
- IC₅₀, 125
 Ifosfamide, 19
 Ilmofofosine, 43
- Immunomodulators, 253
 Immunoreactivity, 9S
 Immunotoxins, 443
In vitro testing, 687
In vivo, 311
 Inferior petrosal sinus sampling, 555
 Interferon, 147, 413, 687,
 α , 281, 567
 α 2b, 5S, 9S, 13S, 19S, 25S, 29S, 33S, 39S
 Intrapatient escalation scheme, 225
 Intravesical
 immunotherapy, 39
 interferon- α 2b, 13S
 therapy, 9S, 25S, 39S
 Ionophores, 443
- Keto-C-glycosides, 351
- L-phenylalanine mustard, 125
 L1210 mouse leukemia, 401
 Lactic acid oligomer microspheres, 237
 Lectins, 507
 Leucovorin, 463
 Leukemia, 273, 475
 L121 mouse, 401
 P388 cell, 233
 LH-RH analogs, 109
 Lhermitte's sign, 375
 Liposome(s), 9S, 101, 443
 Local chemotherapy, 261
 Locoregional chemotherapy, 17
 LoVo, 413
 Luteinizing hormone releasing
 hormone agonist, 3
 Lymph node metastases, 233
 Lymphokine activated killer cells, 155
 Lysergol, 609
- Macrophage activation, 665
 Magnetic resonance imaging, 541
 Malignant
 cells, 525
 pleural effusion, 17
 Mammary
 carcinogenesis, 623
 carcinoma, 629
 Melatonin, 623
 Membrane, 651
 redox activity, 615
 Metastasis, 101, 233, 413, 455
 Metastatic disease, 3
 Methemoglobinemia, 331
 Methotrexate, 471, 589
 Methylglyoxal bis(butylamidino-hydrazone), 683
 Metoclopramide, 267
 Microspheres, 47
 Mistletoe, 507
 Mitomycin, 471
 C, 33S, 39S
 Mitoxantrone, 17, 471, 475, 647
- Mononuclear cells, 5S
 Morphine, 91
 MTT assay, 33
 Multidrug resistance, 359, 419
 Multiple myeloma, 641
 MXT mammary tumor, 109
- N-(2-Hydroxypropyl)methacrylamide, 175
 N-Acetylcysteine, 19
 N-Butyl-2,3-dihydrophthalazine-1,4-dione, 55
 Na⁺, K⁺-ATPase, 651
 Naloxone, 91
 Natural
 carotenoid, 493
 killer cells, 5S, 9S
 suppressor cells, 427
 Neoadjuvant therapy, 413
 Neurobehavioral disturbance, 567
 Neurotoxicity, 371, 375, 567
 Nobiletin, 525
 Nucleoid sedimentation, 499
 Nude mouse (mice), 387, 413
 studies, 531
- O⁶-methylguanine, 401
 Octreotide, 555
 Oncogene expression, 281
 Ondansetron, 79
 Osteocalcin, 87
 Ovarian cancer, 395
- P388
 leukemia cell, 233
 tumor cells, 419
 Palliative therapy, 17
 Pancreatic cancer, 211
 Partial hepatectomy, 117
 Perrimustine, 225
 pH, 651
 Pharmacokinetic study, 337
 Pharmacokinetics, 19, 593
 Phase
 I, 219, 225
 trial(s) 337, 571
 II study, 211
 Photosensitization, 139
 Phthalocyanines, 139
 Pituitary tumor, 555
 Plasmanyl-(N-acyl)-ethanolamine, 513
 Platinum, 9S
 Pleurodesis, 17
 Polyethyleneglycol, 175
 Polymeric drug carriers, 175
 Preclinical, 311
 Proliferation, 147, 245
- Quality of life, 571
 Quercetin, 525
 Quiescent, 245

Key word index to Volume 3

- Rat, 117
 thymocytes, 499
RC-160, 519
Recombinant tumor necrosis factor, 211
Recurrence, 39
Reduced toxicity, 101
Renal cell carcinoma, 567
Resistance
 modifiers, 641
 modifying agent, 419
Respiration, 63
Rhein, 407, 615
Rhodamine-123, 419
Ruthenium complexes, 25

Salvage chemotherapy, 471, 481
Sarcoma, 519, 541
SDI test, 33
SDZ PSC-833, 641
Selectivity, 351
Sensitizer, 267
Skin cancer, 481
Small cell lung cancer, 359
SMANCS, 175
Solid mouse tumors, 25

Somatostatin, 519
 analog, 555
Squamous cell carcinoma, 481
Steroid receptors, 147
Stomach, 33
Structure-activity relationship, 351
Sulofenur, 331
Superficial
 bladder cancer, 25S, 29S
 tumor, 39
Suramin, 91, 499
Synergism, 635
Synergy, 577

T lymphocytes, 5S, 9S
T₈ sarcoma of Guérin, 9
Tangeretin, 525
Taxol, 121, 311
Taxotere, 121
Temozolomide, 401
Teniposide, 245
Testicle, 589
1-(2-Tetrahydrofuryl)-5-fluorouracil, 117
Thioguanine, 475
Thiol groups, 63

Thiotepa, 39S
Topoisomerase 1 inhibitor, 337
Topotecan, 337
Toxicity, 47, 95, 237
Toxins, 507
Trimethoxybenzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390), 387
Tropisetron, 79
TT-62, 289
Tumor
 cells, 121
 colony forming units, 143
 growth, 541
Tumoral cells, 351
Tunica vaginalis, 589

Urinary bladder, 39

Vascular endothelial cell growth inhibition, 293
Vincristine, 371

X-rays, 133

Yoshida ascite sarcoma, 9